CA2375083A1 - Clear oil-containing pharmaceutical compositions - Google Patents

Clear oil-containing pharmaceutical compositions Download PDF

Info

Publication number
CA2375083A1
CA2375083A1 CA002375083A CA2375083A CA2375083A1 CA 2375083 A1 CA2375083 A1 CA 2375083A1 CA 002375083 A CA002375083 A CA 002375083A CA 2375083 A CA2375083 A CA 2375083A CA 2375083 A1 CA2375083 A1 CA 2375083A1
Authority
CA
Canada
Prior art keywords
peg
pharmaceutical composition
oil
glyceryl
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002375083A
Other languages
French (fr)
Other versions
CA2375083C (en
Inventor
Feng-Jing Chen
Mahesh V. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipocine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375083A1 publication Critical patent/CA2375083A1/en
Application granted granted Critical
Publication of CA2375083C publication Critical patent/CA2375083C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeuti c agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.

Claims (184)

1. A pharmaceutical composition comprising:
(a) a triglyceride;
(b) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic; and (c) a therapeutic agent which is capable of being solubilized in the triglyceride, the carrier, or both the triglyceride and the carrier, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion.
2. The pharmaceutical composition of claim 1, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, modified triglycerides, fractionated triglycerides, and mixtures thereof.
3. The pharmaceutical composition of claim 1, wherein the triglyceride is selected from the group consisting of almond oil; babassu oil; borage oil;
blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil;
evening primrose oil;
grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil;
sunflower oil;
hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil;
hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; modified triglycerides; fractionated triglycerides; and mixtures thereof.
4. The pharmaceutical composition of claim 1, wherein the triglyceride is selected from the group consisting of coconut oil; corn oil; olive oil; palm oil; peanut oil;
safflower oil; sesame oil; soybean oil; hydrogenated castor oil; hydrogenated coconut oil;
partially hydrogenated soybean oil; glyceryl tricaprate; glyceryl trilaurate;
glyceryl trioleate; glyceryl trilinoleate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; modified triglycerides; fractionated triglycerides; and mixtures thereof.
5. The pharmaceutical composition of claim 1, wherein the triglyceride is a medium chain triglyceride, a long chain triglyceride, a modified triglyceride, a fractionated triglyceride, or a mixture thereof.
6. The pharmaceutical composition of claim 1, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.
7. The pharmaceutical composition of claim 1, wherein the hydrophilic surfactant comprises at least one ionic surfactant.
8. The pharmaceutical composition of claim 6, which further comprises at least one ionic surfactant.
9. The pharmaceutical composition of claim 6, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides;
alkylmaltosides;
alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers;
polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters;
polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; sugar esters, sugar ethers;
sucroglycerides; and mixtures thereof.
10. The pharmaceutical composition of claim 6, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils;
reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
11. The pharmaceutical composition of claim 10, wherein the glyceride is a monoglyceride, diglyceride, triglyceride, or a mixture thereof.
12. The pharmaceutical composition of claim 10, wherein the reaction mixture comprises the transesterification products of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
13. The pharmaceutical composition of claim 10, wherein the polyol is glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, or a mixture thereof.
14. The pharmaceutical composition of claim 6, wherein the hydrophilic surfactant is PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer, or a mixture thereof.
15. The pharmaceutical composition of claim 6, wherein the hydrophilic surfactant is PEG-20 laurate, PEG-20 oleate, PEG-35 castor oil, PEG-40 palm kernel oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, polyglyceryl-10 laurate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, PEG-30 cholesterol, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, PEG-24 cholesterol, sucrose monostearate, sucrose monolaurate, a poloxamer, or a mixture thereof.
16. The pharmaceutical composition of claim 6, wherein the hydrophilic surfactant is PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, or a mixture thereof.
17. The pharmaceutical composition of claim 7, wherein the ionic surfactant is selected from the group consisting of alkyl ammonium salts; bile salts, analogues, and derivatives thereof; fusidic acid and derivatives thereof; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides;
alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins; lysophospholipids and derivatives thereof;
carnitine fatty acid ester salts; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; and mixtures thereof.
18. The pharmaceutical composition of claim 7, wherein the ionic surfactant is selected from the group consisting of bile acids and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof;
carnitine fatty acid ester salts; salts of alkylsulfates; salts of fatty acids; sodium docusate;
acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; and mixtures thereof.
19. The pharmaceutical composition of claim 7, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, chenodeoxycholate, glycodeoxycholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, lithocholate, tauroursodeoxycholate, glycoursodeoxycholate, cholylsarcosine, N-methyl taurocholate, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, tetraacetyl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
20. The pharmaceutical composition of claim 7, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, lysophosphatidylcholine, PEG-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, chenodeoxycholate, lithocholate, ursodeoxycholate, taurodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate, caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
21. The pharmaceutical composition of claim 7, wherein the ionic surfactant is selected from the group consisting of lecithin, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, chenodeoxycholate, lithocholate, ursodeoxycholate, taurocholate, caprylate, caprate, oleate, lauryl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
22. The pharmaceutical composition of claim 1, wherein the carrier comprises at least two hydrophilic surfactants.
23. The pharmaceutical composition of claim 1, wherein the carrier comprises at least one hydrophilic surfactant and at least one hydrophobic surfactant.
24. The pharmaceutical composition of claim 1 wherein the hydrophobic surfactant is a compound or mixture of compounds having an HLB value less than about 10.
25. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is selected from the group consisting of alcohols; polyoxyethylene alkylethers;

fatty acids; bile acids; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; polyethylene glycol fatty acids esters;
polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters;
polyoxyethylene glycerides; lactic acid derivatives of mono/diglycerides; propylene glycol diglycerides;
sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols;
sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils;
polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
26. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is selected from the group consisting of fatty acids; bile acids;
lower alcohol fatty acid esters; polyethylene glycol glycerol fatty acid esters;
polypropylene glycol fatty acid esters; polyoxyethylene glycerides; glycerol fatty acid esters;
acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters;
polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols;
and mixtures thereof.
27. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is selected from the group consisting of bile acids; lower alcohol fatty acids esters; polypropylene glycol fatty acid esters; propylene glycol fatty acid esters; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene vegetable oils;
and mixtures thereof.
28. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is a glycerol fatty acid ester, an acetylated glycerol fatty acid ester, or a mixture thereof.
29. The pharmaceutical composition of claim 28, wherein the glycerol fatty acid ester is a monoglyceride, diglyceride, or a mixture thereof.
30. The pharmaceutical composition of claim 29, wherein the fatty acid of the glycerol fatty acid ester is a C6 to C22 fatty acid or a mixture thereof.
31. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is a reaction mixture of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
32. The pharmaceutical composition of claim 31, wherein the reaction mixture is a transesterification product of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
33. The pharmaceutical composition of claim 31, wherein the polyol is polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, or a mixture thereof.
34. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is selected from the group consisting of myristic acid; oleic acid;
lauric acid;
stearic acid; palmitic acid; PEG 1-4 stearate; PEG 2-4 oleate; PEG-4 dilaurate; PEG-4 dioleate; PEG-4 distearate; PEG-6 dioleate; PEG-6 distearate; PEG-8 dioleate;

castor oil; PEG 5-10 hydrogenated castor oil; PEG 6-20 corn oil; PEG 6-20 almond oil;
PEG-6 olive oil; PEG-6 peanut oil; PEG-6 palm kernel oil; PEG-6 hydrogenated palm kernel oil; PEG-4 capric/caprylic triglyceride, mono, di, tri, tetra esters of vegetable oil and sorbitol; pentaerythrityl di, tetra stearate, isostearate, oleate, caprylate, or caprate;
polyglyceryl 2-4 oleate, stearate, or isostearate; polyglyceryl 4-10 pentaoleate;
polyglyceryl-3 dioleate; polyglyceryl-6 dioleate; polyglyceryl-10 trioleate;
polyglyceryl-3 distearate; propylene glycol mono- or diesters of a C6 to C22 fatty acid;
monoglycerides of a C6 to C22 fatty acid; acetylated monoglycerides of C6 to C22 fatty acid;
diglycerides of C6 to C22 fatty acids; lactic acid derivatives of monoglycerides; lactic acid derivatives of diglycerides; cholesterol; phytosterol; PEG 5-20 soya sterol; PEG-6 sorbitan tetra, hexastearate; PEG-6 sorbitan tetraoleate; sorbitan monolaurate; sorbitan monopalmitate;
sorbitan mono, trioleate; sorbitan mono, tristearate; sorbitan monoisostearate; sorbitan sesquioleate; sorbitan sesquistearate; PEG 2-5 oleyl ether; POE 2-4 lauryl ether; PEG-2 cetyl ether; PEG-2 stearyl ether; sucrose distearate; sucrose dipalmitate;
ethyl oleate;
isopropyl myristate; isopropyl palmitate; ethyl linoleate; isopropyl linoleate; poloxamers;
cholic acid; ursodeoxycholic acid; glycocholic acid; taurocholic acid;
lithocholic acid;
deoxycholic acid; chenodeoxycholic acid; and mixtures thereof.
35. The pharmaceutical composition of claim 24, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid; lauric acid;
glyceryl monocaprate; glyceryl monocaprylate; glyceryl monolaurate; glyceryl monooleate;
glyceryl dicaprate; glyceryl dicaprylate; glyceryl dilaurate; glyceryl dioleate; acetylated monoglycerides; propylene glycol oleate; propylene glycol laurate;
polyglyceryl-3 oleate;
polyglyceryl-6 dioleate; PEG-6 corn oil; PEG-20 corn oil; PEG-20 almond oil;
sorbitan monooleate; sorbitan monolaurate; POE-4 lauryl ether; POE-3 oleyl ether; ethyl oleate;
poloxamers; cholic acid; ursodeoxycholic acid; glycocholic acid; taurocholic acid;
lithocholic acid; deoxycholic acid; chenodeoxycholic acid; and mixtures thereof.
36. The pharmaceutical composition of claim 1, wherein the therapeutic agent is a drug, a vitamin, a nutritional supplement, a cosmeceutical, or a mixture thereof.
37. The pharmaceutical composition of claim 1, wherein the therapeutic agent is a hydrophobic drug.
38. The pharmaceutical composition of claim 37, wherein the hydrophobic drug has a molecular weight of less than about 1000 g/mol.
39. The pharmaceutical composition of claim 1, wherein the therapeutic agent is a hydrophilic drug.
40. The pharmaceutical composition of claim 39, wherein the hydrophilic drug is a peptidomimetic, a peptide, a protein, an oligonucleotide, an oligodeoxynucleotide, RNA, DNA, genetic material, derivatives or analogues thereof, or a mixture thereof.
41. The pharmaceutical composition of claim 39, wherein the hydrophilic drug has a molecular weight of less than about 1000 g/mol.
42. The pharmaceutical composition of claim 1, wherein the surfactants are present in amounts such that the triglyceride can be present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having only one surfactant, the surfactant being hydrophilic, and having the same total surfactant concentration.
43. The pharmaceutical composition of claim 22, wherein the surfactants are present in amounts such that the triglyceride can be present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having only one surfactant, the surfactant being hydrophilic, and having the same total surfactant concentration.
44. The pharmaceutical composition of claim 23, wherein the surfactants are present in amounts such that the triglyceride can be present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having a hydrophilic surfactant but not having a hydrophobic surfactant, and having the same total surfactant concentration.
45. The pharmaceutical composition of claim 1, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to composition ratio of about 10:1 by weight, the composition forms a clear aqueous dispersion.
46. The pharmaceutical composition of claim 1, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to composition ratio of about 100:1 by weight, the composition forms a clear aqueous dispersion.
47. The pharmaceutical composition of claim 46, wherein the clear aqueous dispersion has an absorbance of less than about 0.3 at about 400 nm.
48. The pharmaceutical composition of claim 47, wherein the absorbance is less than about 0.2.
49. The pharmaceutical composition of claim 47, wherein the absorbance is less than about 0.1.
50. The pharmaceutical composition of claim 1, which further comprises a solubilizer.
51. The pharmaceutical composition of claim 50, wherein the solubilizer is selected from the group consisting of alcohols, polyols, amides, esters, propylene glycol ethers and mixtures thereof.
52. The pharmaceutical composition of claim 51, wherein the alcohol or polyol is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, maltol, maltodextrins, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives, and mixtures thereof.
53. The pharmaceutical composition of claim 51, wherein the amide is selected from the group consisting of 2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
54. The pharmaceutical composition of claim 51, wherein the ester is selected from the group consisting of ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, .epsilon.-caprolactone and isomers thereof, .delta.-valerolactone and isomers thereof, .beta.-butyrolactone and isomers thereof, and mixtures thereof.
55. The pharmaceutical composition of claim 50, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and derivatives thereof, ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol diacetate, .epsilon.-caprolactone and isomers thereof, .delta.-valerolactone and isomers thereof, .beta.-butyrolactone and isomers thereof, 2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethyl pyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, glycofurol, methoxy PEG, and mixtures thereof.
56. The pharmaceutical composition of claim 50, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, ethylene glycol, propylene glycol, 1,3-butanediol, glycerol, pentaerythritol, sorbitol, glycofurol, transcutol, dimethyl isosorbide, polyethylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxypropylcyclodextrins, sulfobutyl ether derivatives of cyclodextrins, ethyl propionate, tributylcitrate, triethylcitrate, ethyl oleate, ethyl caprylate, triacetin, .beta.-butyrolactone and isomers thereof, 2-pyrrolidone, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethylpyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
57. The pharmaceutical composition of claim 50, wherein the solubilizer is triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, dimethyl isosorbide, or a mixture thereof.
58. The pharmaceutical composition of claim 50, wherein the solubilizer is triacetin, ethanol, polyethylene glycol 400, glycofurol, propylene glycol or a mixture thereof.
59. The pharmaceutical composition of claim 1, which further comprises an antioxidant, a bufferant, an antifoaming agent, a detackifier, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, a filler, a plasticizer, a lubricant, or a mixture thereof.
60. The pharmaceutical composition of claim 1, which further comprises an amount of an enzyme inhibiting agent sufficient to at least partially inhibit enzymatic degradation of the therapeutic agent.
61. The pharmaceutical composition of claim 60, wherein the enzyme inhibitor is solubilized or suspended in the preconcentrate.
62. The pharmaceutical composition of claim 1, which further comprises an aqueous medium comprising water, an aqueous palatable diluent or an aqueous beverage.
63. The pharmaceutical composition of claim 62, wherein the therapeutic agent is provided to the composition in the aqueous medium.
64. The pharmaceutical composition of claim 62, wherein the aqueous medium further comprises an amount of an enzyme inhibiting agent sufficient to at least partially inhibit enzymatic degradation of the therapeutic agent.
65. The pharmaceutical composition of claim 1 in the form of a preconcentrate in a liquid, semi-solid, or solid form, or as an aqueous or organic diluted preconcentrate.
66. A dosage form comprising the pharmaceutical composition of claim 1 processed by lyophilization, encapsulation, extruding, compression, melting, molding, spraying, coating, comminution, mixing, homogenization, sonication, granulation, or a combination thereof.
67. A dosage form comprising the pharmaceutical composition of claim 1 formulated as a pill, capsule, caplet, tablet, granule, bead or powder.
68. The dosage form of claim 67, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule or a soft gelatin capsule.
69. The dosage form of claim 67, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
70. The dosage form of claim 67, which further comprises an enteric coating, a seal coating, or both.
71. A dosage form comprising the pharmaceutical composition of claim 1 formulated as a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, syrup or elixer.
72. A dosage form comprising a multiparticulate carrier coated onto a substrate with the pharmaceutical composition of claim 1.
73. The dosage form of claim 72, wherein the substrate is a particle, a granule or a bead, and is formed of the therapeutic agent, a pharmaceutically acceptable material, or a mixture thereof.
74. The dosage form of claim 72, wherein the multiparticulate carrier is enteric coated, seal coated, or both.
75. The pharmaceutical composition of claim 1, which further comprises an additional amount of the therapeutic agent, said additional amount not solubilized in the composition.
76. The dosage form of claim 72, wherein the dosage form is further processed by encapsulation, compression, extrusion or molding.
77. The dosage form of claim 72, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule, or a soft gelatin capsule.
78. The dosage form of claim 72, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
79. A pharmaceutical composition comprising:
(a) a triglyceride;
(b) a carrier comprising at least one hydrophilic surfactant and at least one hydrophobic surfactant; and (c) a therapeutic agent which is capable of being solubilized in the triglyceride, the carrier, or both the triglyceride and the carrier, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion.
80. The pharmaceutical composition of claim 79, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, modified triglycerides, fractionated triglycerides, and mixtures thereof.
81. The pharmaceutical composition of claim 79, wherein the triglyceride is selected from the group consisting of almond oil; babassu oil; borage oil;
blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil;
evening primrose oil;
grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil;
sunflower oil;
hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil;
hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; modified triglycerides; fractionated triglycerides; and mixtures thereof.
82. The pharmaceutical composition of claim 79, wherein the triglyceride is selected from the group consisting of coconut oil; corn oil; olive oil; palm oil; peanut oil;
safflower oil; sesame oil; soybean oil; hydrogenated castor oil; hydrogenated coconut oil;
partially hydrogenated soybean oil; glyceryl tricaprate; glyceryl trilaurate;
glyceryl trioleate; glyceryl trilinoleate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; modified triglycerides; fractionated triglycerides; and mixtures thereof.
83. The pharmaceutical composition of claim 79, wherein the triglyceride is a medium chain triglyceride, a long chain triglyceride, a modified triglyceride, a fractionated triglyceride, or a mixture thereof.
84. The pharmaceutical composition of claim 79, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.
85. The pharmaceutical composition of claim 79, wherein the hydrophilic surfactant comprises at least one ionic surfactant.
86. The pharmaceutical composition of claim 84, which further comprises at least one ionic surfactant.
87. The pharmaceutical composition of claim 84, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides;
alkylmaltosides;
alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers;
polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters;
polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; sugar esters, sugar ethers;
sucroglycerides; and mixtures thereof.
88. The pharmaceutical composition of claim 84, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils;
reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
89. The pharmaceutical composition of claim 84, wherein the glyceride is a monoglyceride, diglyceride, triglyceride, or a mixture thereof.
90. The pharmaceutical composition of claim 88, wherein the reaction mixture comprises the transesterification products of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
91. The pharmaceutical composition of claim 88, wherein the polyol is glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, or a mixture thereof.
92. The pharmaceutical composition of claim 84, wherein the hydrophilic surfactant is PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer, or a mixture thereof.
93. The pharmaceutical composition of claim 84, wherein the hydrophilic surfactant is PEG-20 laurate, PEG-20 oleate, PEG-35 castor oil, PEG-40 palm kernel oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, polyglyceryl-10 laurate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, PEG-30 cholesterol, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, PEG-24 cholesterol, sucrose monostearate, sucrose monolaurate, a poloxamer, or a mixture thereof.
94. The pharmaceutical composition of claim 84, wherein the hydrophilic surfactant is PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, or a mixture thereof.
95. The pharmaceutical composition of claim 85, wherein the ionic surfactant is selected from the group consisting of alkyl ammonium salts; bile salts, analogues, and derivatives thereof; fusidic acid and derivatives thereof; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides;
alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins; lysophospholipids and derivatives thereof;
carnitine fatty acid ester salts; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; and mixtures thereof.
96. The pharmaceutical composition of claim 85, wherein the ionic surfactant is selected from the group consisting of bile salts, analogues, and derivatives thereof;
lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; salts of fatty acids; sodium docusate; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides;
succinylated monoglycerides; citric acid esters of mono-,diglycerides; and mixtures thereof.
97. The pharmaceutical composition of claim 85, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, chenodeoxycholate, lithocholate, ursodeoxycholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, chenodeoxycholate, glycodeoxycholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, lithocholate, tauroursodeoxycholate, glycoursodeoxycholate, cholylsarcosine, N-methyl taurocholate, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, tetraacetyl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
98. The pharmaceutical composition of claim 85, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, lysophosphatidylcholine, PEG-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, chenodeoxycholate, lithocholate, ursodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate, caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
99. The pharmaceutical composition of claim 85, wherein the ionic surfactant is selected from the group consisting of lecithin, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, chenodeoxycholate, lithocholate, ursodeoxycholate, taurocholate, caprylate, caprate, oleate, lauryl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.
100. The pharmaceutical composition of claim 79 wherein the hydrophobic surfactant is a compound or mixture of compounds having an HLB value less than about 10.
101. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is selected from the group consisting of alcohols; polyoxyethylene alkylethers;
fatty acids; bile acids; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; polyethylene glycol fatty acids esters;
polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters;
polyoxyethylene glycerides; lactic acid derivatives of mono/diglycerides; propylene glycol diglycerides;
sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols;
sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils;
polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
102. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is selected from the group consisting of fatty acids; bile acids;
lower alcohol fatty acid esters; polyethylene glycol glycerol fatty acid esters;
polypropylene glycol fatty acid esters; polyoxyethylene glycerides; glycerol fatty acid esters;
acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters;
polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols;
and mixtures thereof.
103. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is selected from the group consisting of bile acids; lower alcohol fatty acids esters; polypropylene glycol fatty acid esters; propylene glycol fatty acid esters; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene vegetable oils;
and mixtures thereof.
104. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is a glycerol fatty acid ester, an acetylated glycerol fatty acid ester, or a mixture thereof.
105. The pharmaceutical composition of claim 104, wherein the glycerol fatty acid ester is a monoglyceride, diglyceride, or a mixture thereof.
106. The pharmaceutical composition of claim 105, wherein the fatty acid of the glycerol fatty acid ester is a C6 to C22 fatty acid or a mixture thereof.
107. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is a reaction mixture of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
108. The pharmaceutical composition of claim 107, wherein the reaction mixture is a transesterification product of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
109. The pharmaceutical composition of claim 107, wherein the polyol is polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, or a mixture thereof.
110. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is selected from the group consisting of myristic acid; oleic acid;
lauric acid;
stearic acid; palmitic acid; PEG 1-4 stearate; PEG 2-4 oleate; PEG-4 dilaurate; PEG-4 dioleate; PEG-4 distearate; PEG-6 dioleate; PEG-6 distearate; PEG-8 dioleate;

castor oil; PEG 5-10 hydrogenated castor oil; PEG 6-20 corn oil; PEG 6-20 almond oil;
PEG-6 olive oil; PEG-6 peanut oil; PEG-6 palm kernel oil; PEG-6 hydrogenated palm kernel oil; PEG-4 capric/caprylic triglyceride, mono, di, tri, tetra esters of vegetable oil and sorbitol; pentaerythrityl di, tetra stearate, isostearate, oleate, caprylate, or caprate;
polyglyceryl 2-4 oleate, stearate, or isostearate; polyglyceryl 4-10 pentaoleate;
polyglyceryl-3 dioleate; polyglyceryl-6 dioleate; polyglyceryl-10 trioleate;
polyglyceryl-3 distearate; propylene glycol mono- or diesters of a C6 to C22 fatty acid;
monoglycerides of a C6 to C22 fatty acid; acetylated monoglycerides of C6 to C22 fatty acid;
diglycerides of C6 to C22 fatty acids; lactic acid derivatives of monoglycerides; lactic acid derivatives of diglycerides; cholesterol; phytosterol; PEG 5-20 soya sterol; PEG-6 sorbitan tetra, hexastearate; PEG-6 sorbitan tetraoleate; sorbitan monolaurate; sorbitan monopalmitate;
sorbitan mono, trioleate; sorbitan mono, tristearate; sorbitan monoisostearate; sorbitan sesquioleate; sorbitan sesquistearate; PEG 2-5 oleyl ether; POE 2-4 lauryl ether; PEG-2 cetyl ether; PEG-2 stearyl ether; sucrose distearate; sucrose dipalmitate;
ethyl oleate;
isopropyl myristate; isopropyl palmitate; ethyl linoleate; isopropyl linoleate; poloxamers;
cholic acid; ursodeoxycholic acid; glycocholic acid; taurocholic acid;
lithocholic acid;
deoxycholic acid; chenodeoxycholic acid; and mixtures thereof.
111. The pharmaceutical composition of claim 100, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid; lauric acid;
glyceryl monocaprate; glyceryl monocaprylate; glyceryl monolaurate; glyceryl monooleate;
glyceryl dicaprate; glyceryl dicaprylate; glyceryl dilaurate; glyceryl dioleate; acetylated monoglycerides; propylene glycol oleate; propylene glycol laurate;
polyglyceryl-3 oleate;
polyglyceryl-6 dioleate; PEG-6 corn oil; PEG-20 corn oil; PEG-20 almond oil;
sorbitan monooleate; sorbitan monolaurate; POE-4 lauryl ether; POE-3 oleyl ether; ethyl oleate;
poloxamers; cholic acid; ursodeoxycholic acid; glycocholic acid; taurocholic acid;
lithocholic acid; deoxycholic acid; chenodeoxycholic acid; and mixtures thereof.
112. The pharmaceutical composition of claim 79, wherein the therapeutic agent is a drug, a vitamin, a nutritional supplement, a cosmeceutical, or a mixture thereof.
113. The pharmaceutical composition of claim 79, wherein the therapeutic agent is a hydrophobic drug.
114. The pharmaceutical composition of claim 113, wherein the hydrophobic drug has a molecular weight of less than about 1000 g/mol.
115. The pharmaceutical composition of claim 79, wherein the therapeutic agent is a hydrophilic drug.
116. The pharmaceutical composition of claim 115, wherein the hydrophilic drug is a peptidomimetic, a peptide, a protein, an oligonucleotide, an oligodeoxynucleotide, RNA, DNA, genetic material, derivatives or analogues thereof, or a mixture thereof.
117. The pharmaceutical composition of claim 115, wherein the hydrophilic drug has a molecular weight of less than about 1000 g/mol.
118. The pharmaceutical composition of claim 79, wherein the surfactants are present in amounts such that the triglyceride can be present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having a hydrophilic surfactant but not having a hydrophobic surfactant, and having the same total surfactant concentration.
119. The pharmaceutical composition of claim 79, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to composition ratio of about 10:1 by weight, the composition forms a clear aqueous dispersion.
120. The pharmaceutical composition of claim 79, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to composition ratio of about 100:1 by weight, the composition forms a clear aqueous dispersion.
121. The pharmaceutical composition of claim 79, wherein the clear aqueous dispersion has an absorbance of less than about 0.3 at about 400 nm when the composition is diluted with an aqueous solution in an aqueous solution to composition ratio of 100:1 by weight.
122. The pharmaceutical composition of claim 121, wherein the absorbance is less than about 0.2.
123. The pharmaceutical composition of claim 121, wherein the absorbance is less than about 0.1.
124. The pharmaceutical composition of claim 79, which further comprises a solubilizer.
125. The pharmaceutical composition of claim 124, wherein the solubilizer is selected from the group consisting of alcohols, polyols, amides, esters, propylene glycol ethers and mixtures thereof.
126. The pharmaceutical composition of claim 125, wherein the alcohol or polyol is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, maltol, maltodextrins, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives, and mixtures thereof.
127. The pharmaceutical composition of claim 125, wherein the amide is selected from the group consisting of 2-pyrrolidone, 2-piperidone, E-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
128. The pharmaceutical composition of claim 125, wherein the ester is selected from the group consisting of ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, .epsilon.-caprolactone and isomers thereof, .delta.-valerolactone and isomers thereof, .beta.-butyrolactone and isomers thereof, and mixtures thereof.
129. The pharmaceutical composition of claim 124, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and derivatives thereof, ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol diacetate, .epsilon.-caprolactone and isomers thereof, .delta.-valerolactone and isomers thereof, .beta.-butyrolactone and isomers thereof, 2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethyl pyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, glycofurol, methoxy PEG, and mixtures thereof.
130. The pharmaceutical composition of claim 124, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, ethylene glycol, propylene glycol, 1,3-butanediol, glycerol, pentaerythritol, sorbitol, glycofurol, transcutol, dimethyl isosorbide, polyethylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxypropylcyclodextrins, sulfobutyl ether derivatives of cyclodextrins, ethyl propionate, tributylcitrate, triethylcitrate, ethyl oleate, ethyl caprylate, triacetin, .beta.-butyrolactone and isomers thereof, 2-pyrrolidone, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethylpyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
131. The pharmaceutical composition of claim 124, wherein the solubilizer is triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, dimethyl isosorbide, or a mixture thereof.
132. The pharmaceutical composition of claim 124, wherein the solubilizer is triacetin, ethanol, polyethylene glycol 400, glycofurol, propylene glycol or a mixture thereof.
133. The pharmaceutical composition of claim 79, which further comprises an antioxidant, a bufferant, an antifoaming agent, a detackifier, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, a filler, a plasticizer, a lubricant, or a mixture thereof.
134. The pharmaceutical composition of claim 79, which further comprises an amount of an enzyme inhibiting agent sufficient to at least partially inhibit enzymatic degradation of the therapeutic agent.
135. The pharmaceutical composition of claim 134, wherein the enzyme inhibitor is solubilized or suspended in the preconcentrate.
136. The pharmaceutical composition of claim 79, which further comprises an aqueous medium comprising water, an aqueous palatable diluent or an aqueous beverage.
137. The pharmaceutical composition of claim 136, wherein the therapeutic agent is provided to the composition in the aqueous medium.
138. The pharmaceutical composition of claim 136, wherein the aqueous medium further comprises an amount of an enzyme inhibiting agent sufficient to at least partially inhibit enzymatic degradation of the therapeutic agent.
139. The pharmaceutical composition of claim 79 in the form of a preconcentrate in a liquid, semi-solid, or solid form, or as an aqueous or organic diluted preconcentrate.
140. A dosage form comprising the pharmaceutical composition of claim 79 processed by lyophilization, encapsulation, extruding, compression, melting, molding, spraying, coating, comminution, mixing, homogenization, sonication, granulation, or a combination thereof.
141. A dosage form comprising the pharmaceutical composition of claim 79 formulated as a pill, capsule, caplet, tablet, granule, bead or powder.
142. The dosage form of claim 141, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule or a soft gelatin capsule.
143. The dosage form of claim 141, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
144. The dosage form of claim 141, which further comprises an enteric coating, a seal coating, or both.
145. A dosage form comprising the pharmaceutical composition of claim 79 formulated as a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, syrup or elixer.
146. A dosage form comprising a multiparticulate carrier coated onto a substrate with the pharmaceutical composition of claim 79.
147. The dosage form of claim 146, wherein the substrate is a particle, a granule or a bead, and is formed of the therapeutic agent, a pharmaceutically acceptable material, or a mixture thereof.
148. The dosage form of claim 146, wherein the multiparticulate carrier is enteric coated, seal coated, or both.
149. The pharmaceutical composition of claim 79, which further comprises an additional amount of the therapeutic agent, said additional amount not solubilized in the composition.
150. The dosage form of claim 146, wherein the dosage form is further processed by encapsulation, compression, extrusion or molding.
151. The dosage form of claim 146, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule, or a soft gelatin capsule.
152. The dosage form of claim 146, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
153. A pharmaceutical composition comprising:
(a) a triglyceride;
(b) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion;
(c) a first amount of a therapeutic agent, said first amount being solubilized in the triglyceride, the carrier, or both the triglyceride and the carrier;
and (d) a second amount of a therapeutic agent, said second amount not solubilized in the triglyceride or the carrier.
154. A pharmaceutical composition comprising:
(a) a triglyceride; and (b) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion, and wherein the triglyceride is present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having only one surfactant, the surfactant being hydrophilic, and having the same total surfactant concentration.
155. The composition of claim 154, wherein the triglyceride comprises a digestible oil.
156. The pharmaceutical composition of claim 154, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, and mixtures thereof.
157. The pharmaceutical composition of claim 154, wherein the triglyceride is selected from the group consisting of almond oil; babassu oil; borage oil;
blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil;
evening primrose oil;
grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil;
sunflower oil;
hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil;
hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; and mixtures thereof.
158. The pharmaceutical composition of claim 154, wherein the triglyceride is selected from the group consisting of coconut oil; corn oil; olive oil; palm oil; peanut oil;
safflower oil; sesame oil; soybean oil; hydrogenated castor oil; hydrogenated coconut oil;
partially hydrogenated soybean oil; glyceryl tricaprate; glyceryl trilaurate;
glyceryl trioleate; glyceryl trilinoleate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate;
glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides; linoleic glycerides;
caprylic/capric glycerides; and mixtures thereof.
159. The pharmaceutical composition of claim 154, wherein the triglyceride is a medium chain triglyceride, a long chain triglyceride, or a mixture thereof.
160. The pharmaceutical composition of claim 154, which further comprises a therapeutic agent.
161. A method of treating an animal with a therapeutic agent, the method comprising:
(a) providing a dosage form of a pharmaceutical composition comprising:
(i) a triglyceride; and (ii) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion;
(b) providing a therapeutic agent; and (c) administering said dosage form to said animal.
162. The method of claim 161, wherein the dosage form comprises the pharmaceutical composition processed by lyophilization, encapsulation, extruding, compression, melting, molding, spraying, coating, comminution, mixing, homogenization, sonication, granulation, or a combination thereof.
163. The method of claim 161, wherein the dosage form comprises the pharmaceutical composition formulated as a pill, capsule, caplet, tablet, granule, bead or powder.
164. The method of claim 163, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule or a soft gelatin capsule.
165. The method of claim 163, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
166. The method of claim 163, wherein the capsule further comprises an enteric coating, a seal coating, or both.
167. The method of claim 161, wherein the dosage form comprises the pharmaceutical composition formulated as a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, syrup or elixer.
168. The method of claim 161, wherein the dosage form comprises a multiparticulate carrier coated onto a substrate with the pharmaceutical composition.
169. The method of claim 168, wherein the substrate is a particle, a granule or a bead, and is formed of the therapeutic agent, a pharmaceutically acceptable material or a mixture thereof.
170. The method of claim 168, wherein the multiparticulate carrier is enteric coated, seal coated, or both.
171. The method of claim 168, wherein the dosage form is further processed by encapsulation, compression, extrusion or molding.
172. The method of claim 168, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule, or a soft gelatin capsule.
173. The method of claim 168, wherein the capsule is a starch capsule, a cellulosic capsule, or a soft gelatin capsule.
174. The method of claim 161, wherein the therapeutic agent is provided by solubilizing the therapeutic agent in the triglyceride, in the carrier, or in both the triglyceride and the carrier.
175. The method of claim 161, wherein the therapeutic agent is provided separately from the dosage form of the pharmaceutical composition.
176. The method of claim 161, wherein the dosage form is administered by an oral, parenteral, buccal, topical, transdermal, ocular, pulmonary, vaginal, rectal or transmucosal route.
177. The method of claim 161, wherein the animal is a mammal.
178. The method of claim 177, wherein the mammal is a human.
179. A method of increasing the amount of a triglyceride that can be solubilized in a clear aqueous dispersion, the method comprising:
(a) providing a composition comprising a triglyceride and a carrier, the carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic; and (b) dispersing the composition in an aqueous solution, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion, and wherein the triglyceride is present in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having only one surfactant and having the same total surfactant concentration.
180. The method of claim 179, wherein the step of dispersing the composition comprises mixing the composition with an aqueous solution in vitro.
181. The method of claim 179, wherein the step of dispersing the composition comprises allowing the composition to contact an aqueous biological solution in vivo upon administering the composition to an animal.
182. A method of treating an animal with a therapeutic agent, the method comprising:
(a) providing a dosage form of a pharmaceutical composition comprising:
(i) an effective amount of a triglyceride; and (ii) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution the composition forms a clear aqueous dispersion; and (b) administering said dosage form to said animal.
183. The method of claim 182, wherein the effective amount of the triglyceride is a nutritionally effective amount of a digestible oil.
184. The method of claim 182, wherein the effective amount of the triglyceride is an amount sufficient to improve the bioabsorption of a therapeutic agent co-administered with the dosage form of the pharmaceutical composition.
CA2375083A 1999-06-30 2000-06-02 Clear oil-containing pharmaceutical compositions Expired - Lifetime CA2375083C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/345,615 1999-06-30
US09/345,615 US6267985B1 (en) 1999-06-30 1999-06-30 Clear oil-containing pharmaceutical compositions
PCT/US2000/015133 WO2001001960A1 (en) 1999-06-30 2000-06-02 Clear oil-containing pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CA2375083A1 true CA2375083A1 (en) 2001-01-11
CA2375083C CA2375083C (en) 2010-05-04

Family

ID=23355749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2375083A Expired - Lifetime CA2375083C (en) 1999-06-30 2000-06-02 Clear oil-containing pharmaceutical compositions

Country Status (7)

Country Link
US (1) US6267985B1 (en)
EP (2) EP2000130A1 (en)
JP (2) JP2003503440A (en)
AU (1) AU783077B2 (en)
CA (1) CA2375083C (en)
NZ (1) NZ516521A (en)
WO (1) WO2001001960A1 (en)

Families Citing this family (412)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
DE19834814A1 (en) * 1998-08-01 2000-02-03 Beiersdorf Ag Cosmetic and dermatological preparations with an effective content of bile acids, their salts and / or their derivatives
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
DE69939335D1 (en) 1998-12-30 2008-09-25 Dexcel Ltd DISPERSIBLE CONCENTRATE FOR THE ADMINISTRATION OF CYCLOSPORIN
ES2286998T3 (en) * 1999-02-26 2007-12-16 Sanofi-Aventis STABLE FORMULATION CONTAINING FUMAGILLINA.
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ES2231275T3 (en) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. FAB INHIBITORS I.
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1255565A1 (en) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
SE0000773D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
AU2001251650A1 (en) * 2000-04-18 2001-10-30 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
KR100381834B1 (en) * 2000-05-20 2003-04-26 이상득 Solid dispersion system of pranlukast with improved dissolution, and the method thereof
DE10026699A1 (en) * 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6596306B1 (en) * 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
FR2809958B1 (en) * 2000-06-08 2005-01-14 Crinex Lab LIQUID-LIKE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF AN ACTIVE INGREDIENT, WITH UNDEMPLICABLE TASTE, INCLUDING BITTERY TASTE
AU2001266896B2 (en) * 2000-06-16 2006-04-06 Jagotec Ag Improved injectable dispersions of propofol
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
EP1307232B1 (en) * 2000-08-03 2007-03-07 Antares Pharma IPL AG Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
SI1333851T1 (en) * 2000-09-18 2008-02-29 Rpg Life Sciences Ltd Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities
ATE270544T1 (en) 2000-09-22 2004-07-15 Galephar M F SEMI-SOLID MEDICINAL PREPARATION CONTAINING ISOTRETINOIN
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
ATE414511T1 (en) * 2000-12-05 2008-12-15 Los Angeles Childrens Hospital PHARMACEUTICAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR USE THEREOF
US20020119237A1 (en) * 2000-12-22 2002-08-29 Hevey Maurice O. Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis
FR2818905A1 (en) * 2000-12-28 2002-07-05 Cll Pharma MICELLAR COLLOIDAL PHARMACEUTICAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT
US20030065040A1 (en) * 2001-02-01 2003-04-03 Shojaei Amir H. Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DE60230934D1 (en) * 2001-04-06 2009-03-05 Affinium Pharm Inc FAB I INHIBITORS
AU2002308456B2 (en) * 2001-04-18 2005-12-22 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
MXPA03010705A (en) * 2001-05-25 2004-05-27 Cephalon Inc Solid pharmaceutical formulations comprising modafinil.
WO2002100339A2 (en) 2001-06-13 2002-12-19 Biogal Gyogyszergyar Rt. Novel process for preparing rac-bicalutamide and its intermediates
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
AR034813A1 (en) * 2001-07-20 2004-03-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
CN1335182A (en) * 2001-08-08 2002-02-13 华中科技大学 Insulin spray for oral cavity and its prepn process
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
ES2264463T3 (en) * 2001-09-04 2007-01-01 Loders Croklaan B.V. MIXTURES THAT INCLUDE FATTY ACIDS SUBSTITUTED OR DERIVED FROM THESE.
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20030059489A1 (en) * 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
EP1450853A4 (en) * 2001-11-08 2008-04-09 Brigham & Womens Hospital Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
WO2003041665A1 (en) * 2001-11-09 2003-05-22 The Nisshin Oillio, Ltd. Gel-form composition
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EA008072B1 (en) * 2001-12-03 2007-02-27 Новацея, Инк. Pharmaceutical compositions comprising active vitamin d compounds
ATE364391T1 (en) * 2001-12-14 2007-07-15 Jagotec Ag MEDICINAL FORMULATION CONTAINING CICLOSPORINE AND THEREOF USE
ITBS20010111A1 (en) * 2001-12-20 2003-06-20 Paoli Ambrosi Gianfranco De COMPOSITION FOR TOPICAL USE BASED ON THE ETHYL ESTER OF LINOLEIC ACID AND OF THE TRIETYL ESTER OF CITRIC ACID ASSOCIATED WITH OPPORTUN
DE60222803T2 (en) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. ORAL CAPSULE FORMULATION WITH IMPROVED PHYSICAL STABILITY
KR100441167B1 (en) * 2001-12-27 2004-07-21 씨제이 주식회사 Composition of microemulsion preconcentrate
US20030228395A1 (en) * 2002-01-31 2003-12-11 Archer-Daniels Midland Company Isotropic transparent structured fluids
AU2003215884A1 (en) * 2002-02-25 2003-09-09 Lyfjathroun Hf A bioadhesive agent
JP2005526063A (en) * 2002-03-12 2005-09-02 ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ Use of adapalene to treat skin diseases
FR2837670A1 (en) * 2002-03-26 2003-10-03 Longechaud Veronique Fernandez Soft gelatin capsules filled with rice bran oil, useful for nutritional, cosmetic and therapeutic applications
US6623780B1 (en) * 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040013708A1 (en) * 2002-04-10 2004-01-22 Goulson Melanie J. Aqueous dispersible steryl ester compositions
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
ITMI20021033A1 (en) * 2002-05-15 2003-11-17 Acraf WATER OPHTHALMIC COMPOSITION INCLUDING A LIOTROPIC MESOMORPHIC LIPID
JP4526120B2 (en) * 2002-05-22 2010-08-18 日本製薬株式会社 L-Menthol oil-in-water emulsion
EP1506774B1 (en) * 2002-05-22 2011-08-24 Nihon Pharmaceutical Co., Ltd. Smooth muscle peristole inhibitor
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
US7306819B2 (en) 2002-06-12 2007-12-11 The Coca-Cola Company Beverages containing plant sterols
KR20030095600A (en) * 2002-06-12 2003-12-24 환인제약 주식회사 Controlled release composition comprising felodipine, and method of the preparing thereof
MXPA04012456A (en) 2002-06-12 2005-02-17 Coca Cola Co Beverages containing plant sterols.
DE10226201A1 (en) * 2002-06-12 2003-12-24 Ifac Gmbh & Co Kg Inst Fuer An Ether alcohols as solvents and emulsions and dispersions containing them
DE10226990A1 (en) * 2002-06-18 2004-03-18 Sanguibiotech Ag Topically applicable micro-emulsions with binary phase and active substance differentiation, their production and their use, in particular for supplying the skin with bioavailable oxygen
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
KR100573289B1 (en) * 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
KR100533458B1 (en) 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
EP1569515A4 (en) * 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa Methods for vaccinating against malaria
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7374772B2 (en) * 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
TW200409644A (en) * 2002-12-04 2004-06-16 Bio Max Inc Improved carrier system for cyclosporin pharmaceutical compositions
ES2518316T3 (en) 2002-12-06 2014-11-05 Debiopharm International Sa Heterocyclic compounds, their manufacturing methods and their use in therapy
JPWO2004052354A1 (en) * 2002-12-06 2006-04-06 株式会社大塚製薬工場 Propofol-containing fat emulsion
US7166671B2 (en) * 2002-12-10 2007-01-23 Cellresin Technologies, Llc Grafted cyclodextrin
US7385004B2 (en) * 2002-12-10 2008-06-10 Cellresin Technologies, Llc Enhanced lubrication in polyolefin closure with polyolefin grafted cyclodextrin
US8129450B2 (en) 2002-12-10 2012-03-06 Cellresin Technologies, Llc Articles having a polymer grafted cyclodextrin
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
SG182004A1 (en) 2003-01-14 2012-07-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
BRPI0407276A (en) * 2003-02-07 2006-01-31 Prometic Biosciences Inc fatty acids, glycerides and analogues of medium chain length as erythropoiesis stimulants
TWI323660B (en) 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
FR2851918B1 (en) * 2003-03-06 2006-06-16 IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE
DE602004016831D1 (en) 2003-03-17 2008-11-13 Affinium Pharm Inc PHARMACEUTICAL COMPOSITIONS INHIBITORS OF FAB I AND OTHER ANTIBIOTICS CONTAINED
WO2004085715A1 (en) * 2003-03-25 2004-10-07 Toppan Printing Co., Ltd. Method of analyzing electrolytic copper plating solution, and analyzing device therefor and production method for semi-conductor product
ES2360102T3 (en) 2003-03-26 2011-05-31 Egalet A/S SYSTEM FOR CONTROLLED RELEASE OF MORPHINE.
JP4989217B2 (en) * 2003-03-26 2012-08-01 エガレット エイ／エス Matrix composition for controlled delivery of drug substance
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
ZA200510025B (en) * 2003-06-11 2007-03-28 Novacea Inc Pharmaceutical compositions comprising active vitamin D compounds
MXPA05014060A (en) * 2003-06-17 2006-03-17 Sk Corp Transnasal microemulsions containing diazepam.
EP1488785A1 (en) * 2003-06-18 2004-12-22 B. Braun Melsungen Ag Oil emulsion for postnatal substitution of hormones
BRPI0412689A (en) 2003-07-14 2006-10-03 Arena Pharm Inc heteroaryl and fused aryl derivatives as metabolism modulators and the prophylaxis and treatment of related disorders
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US7169401B2 (en) * 2003-07-18 2007-01-30 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
CN1845725A (en) * 2003-08-06 2006-10-11 尼马尔·穆利耶 Pharmaceutical composition containing water soluble drug
JP3881640B2 (en) * 2003-08-08 2007-02-14 塩野義製薬株式会社 Dry syrup containing loratadine
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
SG146638A1 (en) * 2003-09-19 2008-10-30 Drugtech Corp Pharmaceutical delivery system
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
JP2007509981A (en) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド Nanoparticles for drug delivery
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
PE20050596A1 (en) * 2003-12-19 2005-10-18 Novartis Ag MICROEMULSION INCLUDING A RENIN INHIBITOR
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
WO2005070399A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
US20050171177A1 (en) * 2004-01-30 2005-08-04 Thompson Daniel J. Method of treatment of Candida isolates
EP1714656B8 (en) * 2004-02-06 2017-09-20 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
CN1933850B (en) * 2004-03-22 2011-01-12 索尔瓦药物有限公司 Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20080241082A1 (en) * 2004-04-05 2008-10-02 Lonza Inc. Method for the Preparation of Cosmetic Emulsion
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
CN1980574A (en) * 2004-05-06 2007-06-13 锡德克斯公司 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8075910B2 (en) 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
ATE480592T1 (en) * 2004-05-24 2010-09-15 Cellresin Tech Llc AMPHOTERE GRAFTED BARRIER MATERIALS
PL1828167T3 (en) 2004-06-04 2015-02-27 Debiopharm Int Sa Acrylamide derivatives as antibiotic agents
BRPI0418885A (en) * 2004-06-07 2007-11-27 Strides Arcolab Ltd pharmaceutical composition containing a stable and clear solution of soft gelatin capsule anti-inflammatory drug and process for producing it
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
TWI365075B (en) * 2004-09-22 2012-06-01 Kao Corp Microemulsion
JP4147235B2 (en) * 2004-09-27 2008-09-10 キヤノン株式会社 Discharge liquid, discharge method, droplet forming method, liquid discharge cartridge, and discharge apparatus
PL1811979T3 (en) * 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Microcapsules comprising a methylxanthine and a corticosteroid
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
EA014420B1 (en) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
EA200701228A1 (en) * 2004-12-06 2007-12-28 Релайэнт Фармасьютикалз, Инк. STABLE COMPOSITIONS OF PHENOPHIBRATE WITH FATTY ACID ETHERS
CN101132781A (en) * 2004-12-09 2008-02-27 茵西斯医疗公司 Room-temperature stable dronabinol formulations
JP4734909B2 (en) * 2004-12-09 2011-07-27 日油株式会社 Solubilizer composition for poorly water-soluble drugs
JP4734910B2 (en) * 2004-12-09 2011-07-27 日油株式会社 Solubilizer composition for poorly water-soluble drugs
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (en) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. LIQUID FORMULATION
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2006097938A1 (en) * 2005-03-16 2006-09-21 Strides Arcolab Limited Stable liquid suspension formulation comprising tibolone and process for producing the same
CN101141953A (en) * 2005-03-21 2008-03-12 伊瓦克斯制药有限公司 Crystallization inhibitor and its use in gelatin capsules
BRPI0609432A2 (en) * 2005-03-21 2010-04-06 Macusight Inc drug delivery systems for treating diseases or conditions
WO2006099877A1 (en) * 2005-03-24 2006-09-28 Atef Mohammed Mostafa Darwish Rectal and vaginal suppositories containing bioadhesive bromocriptine and poloxamer
JP4646669B2 (en) 2005-03-30 2011-03-09 キヤノン株式会社 Discharge liquid, discharge method, droplet forming method, cartridge, and discharge device
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR20080009201A (en) * 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
CN101170993A (en) * 2005-05-09 2008-04-30 药物技术公司 Modified-release pharmaceutical compositions
ATE543489T1 (en) * 2005-05-26 2012-02-15 Teva Womens Health Inc ORAL DOSAGE FORMS CONTAINING PROGESTERONE AND METHODS OF USE AND MANUFACTURING THEREOF
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US7956031B2 (en) 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
MX2007016021A (en) 2005-06-17 2008-04-16 Australian Nuclear Science Tec Particles having hydrophobic material therein.
CN101242814A (en) 2005-06-17 2008-08-13 澳大利亚核科学技术组织 Particles comprising a releasable dopant therein
DK1906921T3 (en) * 2005-07-08 2009-04-06 Physica Pharma Clear pharmaceutical aqueous microemulsion comprising propofol and method of preparation
KR100699582B1 (en) 2005-07-11 2007-03-23 삼성전기주식회사 Output buffer circuit
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US8288348B2 (en) * 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
JP5584415B2 (en) 2005-10-12 2014-09-03 ユニメッド・ファーマシューティカルズ・エルエルシー Improved testosterone gel formulation and method of use
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
KR20080075027A (en) * 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
KR20080073700A (en) * 2005-12-06 2008-08-11 와이어쓰 Benzimidazole non-aqueous compositions
CA2635986A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
US20070154516A1 (en) * 2006-01-05 2007-07-05 Drugtech Corporation Drug delivery system
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (en) 2006-03-23 2014-05-28 参天製薬株式会社 Formulations and methods for diseases or conditions associated with vascular permeability
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
EA015304B1 (en) 2006-08-03 2011-06-30 Нитек Фарма Аг Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080098900A1 (en) * 2006-11-01 2008-05-01 Babatunde Aremu Beverage manufacture using a static mixer
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20080311093A1 (en) * 2006-12-07 2008-12-18 American Symbolic, Llc Stem cell secretions and related methods
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2380564B1 (en) 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
JP2010526054A (en) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド Combined pharmaceutical composition
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
TWI489983B (en) * 2007-05-22 2015-07-01 Otsuka Pharma Co Ltd A medicament for treating alzheimer's disease
US8076517B2 (en) 2007-05-29 2011-12-13 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
JP2008306942A (en) 2007-06-12 2008-12-25 Fujifilm Corp Dry analysis element for measuring lipase
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
CN106310293A (en) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CN101918019B (en) * 2007-10-08 2014-11-26 奥里尼亚制药有限公司 Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
BRPI0705564B8 (en) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria continuous liquid crystal type system containing co-solvents carrying sparingly soluble substances in water, its process of obtaining and its uses
US7968543B2 (en) * 2007-11-08 2011-06-28 Ambit Biosciences Corporation Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009066299A2 (en) * 2007-11-23 2009-05-28 Rappaport Family Institute For Research Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
HUE032287T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease stabilized, acylated insulin analogues
US8282977B2 (en) 2008-03-20 2012-10-09 Virun, Inc. Compositions containing non-polar compounds
BRPI0909185A2 (en) * 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
US8068218B2 (en) 2008-04-13 2011-11-29 Agilent Technologies, Inc. Water in oil measurement using stabilizer
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
KR101517415B1 (en) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
ES2524699T3 (en) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a vehicle comprising a continuous phase of a hydrophobic substance
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
ES2344674B1 (en) * 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
WO2010019255A1 (en) * 2008-08-13 2010-02-18 Virun, Inc. Compositions containing aminoalkanes and aminoalkane derivatives
PT2343982T (en) 2008-09-17 2017-07-04 Chiasma Inc Pharmaceutical compositions and related methods of delivery
JP5547738B2 (en) * 2008-10-08 2014-07-16 ゾエティス・ダブリュー・エルエルシー Benzimidazole anthelmintic composition
US10400118B2 (en) 2008-10-20 2019-09-03 Plastipak Packaging, Inc. Methods and compositions for direct print having improved recyclability
EA019295B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Synthesis of purine nucleosides and process for preparing them
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9480691B1 (en) 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
WO2010084188A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
DK2471518T3 (en) 2009-05-18 2017-12-04 Sigmoid Pharma Ltd COMPOSITION INCLUDING OIL DROPS
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
TWI471321B (en) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
MY154505A (en) * 2009-06-23 2015-06-30 Univ Putra Malaysia An emulsion system derives from engkabang fat esters
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
CN102612375B (en) * 2009-09-15 2016-01-27 Qlt股份有限公司 Pharmaceutical preparation containing the 9-cis-retinyl ester in lipid vehicle thing
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
NZ601001A (en) * 2009-12-22 2014-07-25 Leo Pharma As Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
BR112012015433B8 (en) 2009-12-22 2020-03-03 Leo Pharma As substantially anhydrous pharmaceutical composition for cutaneous application
SG181916A1 (en) * 2009-12-22 2012-08-30 Abbott Lab Abt-263 capsule
WO2011082384A2 (en) 2009-12-31 2011-07-07 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US8603568B2 (en) * 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility
CN108558740B (en) 2010-01-27 2021-10-19 艾尼纳制药公司 S1P1 receptor modulators and salts thereof
KR101622441B1 (en) * 2010-03-23 2016-05-18 버런, 아이엔씨. Nanoemulsion including sucrose fatty acid ester
EP2552933A1 (en) 2010-03-31 2013-02-06 Gilead Pharmasset LLC Purine nucleoside phosphoramidate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
EP2377556A1 (en) * 2010-04-14 2011-10-19 Cognis IP Management GmbH A compound
AU2011244024B2 (en) 2010-04-19 2015-12-10 Eluminex Biosciences (Suzhou) Limited Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
KR101205186B1 (en) 2010-06-04 2012-11-27 한불화장품주식회사 The cosmetic compositions with the improved permeation of hydrophilic active ingredients
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120232159A1 (en) 2011-03-07 2012-09-13 Tonix Pharmaceuticals, Inc. Methods and Compositions for Treating Depression using Cyclobenzaprine
CN103533962B (en) * 2011-03-14 2018-05-18 药品配送方案有限公司 A kind of ophthalmic composition
EP2540281A1 (en) 2011-06-30 2013-01-02 LEK Pharmaceuticals d.d. Solid self-microemulsifying systems
DE102011108948A1 (en) 2011-07-29 2013-01-31 Achim Göpferich Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions
EP2751072B1 (en) 2011-09-08 2018-11-07 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
ES2644962T3 (en) * 2012-01-03 2017-12-01 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents to treat diabetes
ES2912138T3 (en) 2012-02-01 2022-05-24 Oramed Ltd Compositions containing protease inhibitors, compositions comprising the same, and methods of making and using the same
EP2811847B1 (en) 2012-02-10 2017-12-13 Virun, Inc. Beverage compositions containing non-polar compounds
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
CN104364260B (en) 2012-04-11 2017-02-22 诺和诺德股份有限公司 insulin formulations
EP2858629A1 (en) 2012-06-08 2015-04-15 Leo Laboratories Limited A topical gel composition comprising an ingenol derivative and a solvent mixture
RU2490016C1 (en) * 2012-06-13 2013-08-20 Федеральное государственное бюджетное учреждение "Научный центр неврологии" Российской академии медицинских наук (ФГБУ "НЦН" РАМН) Parenteral composition containing carbamazepine in form of submicron emulsion possessing anticonvulsant activity
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014050851A1 (en) * 2012-09-27 2014-04-03 大正製薬株式会社 Oral liquid composition
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
US9682148B2 (en) 2012-12-20 2017-06-20 Solural Pharma ApS Solid oral dosage form of testosterone derivative
MX2015009045A (en) 2013-01-14 2015-12-17 Infirst Healthcare Ltd Compositions and methods for treating severe pain.
AU2014211715B2 (en) 2013-02-04 2016-08-25 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
EP2983525B1 (en) 2013-03-15 2017-12-13 Virun, Inc. Compositions comprising water-soluble derivatives of vitamin e
CA3119755A1 (en) 2013-03-15 2014-09-18 Tonix Pharma Holdings Limited Eutectic formulations of amitriptyline hydrochloride and mannitol
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
CN105188670B (en) 2013-03-15 2018-11-02 马留斯医药有限责任公司 Emulsion formulations
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
ES2502691B1 (en) * 2013-09-25 2015-07-07 Sani-Red, S.L. Protein preservation and stabilization method, applicable for industrial developments of medical, pharmaceutical and cosmetic formulations
US11219606B2 (en) * 2013-10-11 2022-01-11 University Of Florida Research Foundation, Inc. Method of manufacturing stable emulsions and compositions containing the same
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AU2014349256B2 (en) * 2013-11-14 2020-04-30 Lipidor Ab Sprayable topical carrier and composition comprising phosphatidylcholine
EP2878311A1 (en) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
ES2784235T3 (en) 2014-01-20 2020-09-23 Xeda International Antigerminative compositions for coating bulbs and tubers and their use for antigerminative treatment
JP6723166B2 (en) 2014-06-19 2020-07-15 ソルラル ファーマ エーピーエス Solid oral dosage form of lipophilic compound
US9284583B2 (en) * 2014-07-16 2016-03-15 Eastman Chemical Company Enzyme-catalyzed polyoxyalkylene esters
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
WO2016025401A1 (en) * 2014-08-09 2016-02-18 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
AU2015317336B2 (en) 2014-09-18 2021-01-21 Tonix Pharma Holdings Limited Eutectic formulations of Cyclobenzaprine hydrochloride
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
JP6542519B2 (en) * 2014-09-29 2019-07-10 ロレアル Composition
WO2016066611A1 (en) * 2014-10-31 2016-05-06 Capsugel Belgium N.V. Pharmaceutical compositions containing cinacalcet and methods for their preparation and use
ES2858517T3 (en) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Compositions comprising cyclosporin
MX2017008925A (en) 2015-01-06 2017-10-11 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
US9649384B2 (en) * 2015-04-09 2017-05-16 Professional Compounding Centers Of America Natural solubilizer agent comprising a synergistic blend of heptyl glucoside and olive oil glycereth-8 esters for transdermal compositions
RU2708254C2 (en) 2015-05-28 2019-12-05 Др. Редди'С Лабораториз Лтд. Oral celecoxib composition for treating pain
WO2016194942A1 (en) * 2015-06-05 2016-12-08 マルホ株式会社 External preparation for transdermal administration
KR102603199B1 (en) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta for use in S1P1 receptor-related disorders [Ｂ]Indole-3-yl)crystalline L-arginine salt of acetic acid (Compound 1)
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3124016B1 (en) 2015-07-31 2019-09-04 Warszawski Uniwersytet Medyczny Antipsoriatic emulsion composition comprising cefazolin
US9872832B2 (en) * 2015-10-23 2018-01-23 LG Bionano, LLC Nanoemulsions having reversible continuous and dispersed phases
WO2017095736A1 (en) * 2015-12-01 2017-06-08 R.P. Scherer Technologies, Llc Aspirin soft gelatin capsule as a single active or in combination with other actives
PL3419628T3 (en) 2016-02-26 2021-05-31 Debiopharm International Sa Medicament for treatment of diabetic foot infections
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR20190071693A (en) * 2016-10-19 2019-06-24 가부시키가이샤 시세이도 Detergent composition
AU2016247173B2 (en) * 2016-10-21 2023-02-16 LG Bionano, LLC Nanoemulsions having reversible continuous and dispersed phases
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
TWI700092B (en) 2016-12-16 2020-08-01 丹麥商諾佛．儂迪克股份有限公司 Insulin containing pharmaceutical compositions
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11517557B2 (en) 2017-07-13 2022-12-06 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitriptyline
CN111447971A (en) 2017-12-11 2020-07-24 通尼克斯制药控股有限公司 Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CA3091678A1 (en) * 2018-02-26 2019-08-29 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
US11433024B2 (en) 2018-04-27 2022-09-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form
US20220347122A1 (en) * 2019-03-15 2022-11-03 Ftf Pharma Private Limited Solutions for oral dosage
US20220192996A1 (en) * 2019-03-29 2022-06-23 Sekisui Chemical Co., Ltd. Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product
CN114245737A (en) 2019-06-11 2022-03-25 司斐股份有限公司 Microemulsion compositions
US10590038B1 (en) 2019-07-01 2020-03-17 Maw-Tien Lee Producing cementitious materials with improved hydrophobicity and strength using reclaimed waste substances
US20210059278A1 (en) * 2019-09-04 2021-03-04 Pepsico, Inc. Process for preparing transparent emulsions
EP4025067A4 (en) * 2019-09-06 2023-09-13 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
WO2023081786A1 (en) * 2021-11-04 2023-05-11 Vdf Futureceuticals, Inc Ketone precursors and methods therefor
WO2023209136A1 (en) 2022-04-29 2023-11-02 Sifi S.P.A. Microemulsion pharmaceutical composition for treatment of disorders of the anterior segment of the eye
CN115463070B (en) * 2022-06-27 2023-08-22 广东梵蜜琳生物科技有限公司 Hybrid flower extract and preparation method thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886294A (en) * 1973-03-12 1975-05-27 Hoffmann La Roche Carotenoid coloring compositions and preparation thereof
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4146499A (en) * 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
FI65914C (en) * 1978-03-07 1984-08-10 Sandoz Ag FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
US4731384A (en) * 1983-07-01 1988-03-15 Troponwerke Gmbh & Co, Kg Etofenamate formulation
DE3406497A1 (en) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
DE3500103A1 (en) * 1985-01-04 1986-07-10 R.P. Scherer GmbH, 6930 Eberbach PHARMACEUTICAL PREPARATION WITH AN INTENSIVE SOLUTION IN WATER AND DIGESTIVE JUICES
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
JP2588413B2 (en) * 1987-12-14 1997-03-05 ライオン株式会社 Method for producing oil-in-water emulsion
US5244925A (en) * 1987-12-18 1993-09-14 Kabi Pharmacia Aktiebolag Emulsion for parenteral administration
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DE3919982A1 (en) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh ORAL LIPID MEDICINE FORM
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
ATE121618T1 (en) 1990-08-13 1995-05-15 David W Yesair MIXED LIPID-BICARBONATE COLLOIDAL PARTICLES FOR DELIVERING MEDICINAL AND CALORIES.
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5300529A (en) * 1991-02-12 1994-04-05 Isp Investments Inc. Stable, clear, efficacious aqueous microemulsion compositions containing a high loading of a water-insoluble, agriculturally active chemical
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
SE9200951D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
IT1255449B (en) 1992-06-30 1995-10-31 Fabio Berlati USE OF NOR- AND HOMO-DERIVATIVES OF BILE ACIDS AS DRUGS ABSORPTION PROMOTERS.
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
AU686149B2 (en) 1993-04-19 1998-02-05 Institute For Advanced Skin Research Inc. Microemulsion preparation containing difficultly absorbable substance
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
WO1995014037A1 (en) 1993-11-17 1995-05-26 Ibah, Inc. Transparent liquid for encapsulated drug delivery
DE4340781C3 (en) 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
GB9405041D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel process
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5817320A (en) 1994-06-20 1998-10-06 The United States Of America As Represented By The Secretary Of The Agriculture In ovo immunization of avian embryos with oil-emulsion vaccines
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
JP2740153B2 (en) 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー Mixed micelle
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
GB9519468D0 (en) * 1995-09-23 1995-11-22 Smithkline Beecham Plc Novel process
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
KR0183449B1 (en) * 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule preparations
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19939756A1 (en) * 1999-08-21 2001-02-22 Merck Patent Gmbh New 1-(1-ethyl-piperidin-4-yl)-1-(phenyl or heterocyclyl)-alkanol derivatives, are 5-HT(2A) receptor antagonists useful e.g. for treating schizophrenia, depression, memory disorders or eating disorders

Also Published As

Publication number Publication date
AU783077B2 (en) 2005-09-22
AU5313100A (en) 2001-01-22
WO2001001960A1 (en) 2001-01-11
EP1194120A1 (en) 2002-04-10
JP2003503440A (en) 2003-01-28
EP1194120A4 (en) 2005-06-15
EP2000130A1 (en) 2008-12-10
US6267985B1 (en) 2001-07-31
JP2011201914A (en) 2011-10-13
NZ516521A (en) 2003-11-28
CA2375083C (en) 2010-05-04

Similar Documents

Publication Publication Date Title
CA2375083A1 (en) Clear oil-containing pharmaceutical compositions
JP5758812B2 (en) Steroid composition
AU2010203457B2 (en) Steroidal compositions
JP2003503440A5 (en)
EP0415922A1 (en) Integrity protected gelatin
US20100136105A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2002537317A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
CN101652141A (en) The adjustment release dosage form of tacrolimus
US20110263552A1 (en) Modulation of side effect profile of 5-alpha reductase inhibitor therapy
EP2512448B1 (en) Pharmaceutical oral dosage form containing a synthetic oligosaccharide
WO1996037192A1 (en) Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
EP2308496A2 (en) Formulation containing phosphate derivatives of electron transfer agents
JP2740465B2 (en) A novel pharmacological dosage form for transdermal administration
BR112012015016B1 (en) PHARMACEUTICAL FORMULATION, ENTERIC PHARMACEUTICAL DOSAGE FORM AND USE OF A FORMULATION
US6419937B1 (en) Lipoprotein creams
US8758820B2 (en) Robust pellet
KR20010014080A (en) Pharmaceutical composition
KR20230011997A (en) Compositions for Delivery of Bioactive Agents to Hair Follicles

Legal Events

Date Code Title Description
EEER Examination request